Research progress on diabetes patients combined with COVID-19 infection

doi:10.16138/j.1673-6087.2024.01.14

Abstract

Abstract:

Diabetic patients are not only susceptible population to COVID-19 infection，but also prone to develop immune imbalance, excessive inflammatory responses, multi-organ dysfunction, and other complications after infection, resulting in complicated condition and a significantly increased risk of critical illness. Therefore, it requires more attention of clinicians. The article reviews the relevant domestic and international literatures and summarizes the mechanisms of abnormal glucose metabolism induced by COVID-19 infection, clinical characteristics of diabetes patients infected with COVID-19, and the principles of blood glucose management, to improve the clinical understanding and treatment success rate of such patients.

Key words: Severe acute respiratory syndrome coronavirus 2, Diabetes mellitus, Angiotensin-converting enzyme 2, Cytokine storm

CLC Number:

R511
R587

HUANG Xianna, CHEN Yunce, ZHOU Min, NI Lei. Research progress on diabetes patients combined with COVID-19 infection[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(01): 77-81.

References 33

[1]	Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA, 2017, 317(24):2515-2523. doi: 10.1001/jama.2017.7596 pmid: 28655017
[2]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5 URL
[3]	Liu F, Long X, Zhang B, et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection[J]. Clin Gastroenterol Hepatol, 2020, 18(9):2128-2130. doi: 10.1016/j.cgh.2020.04.040 URL
[4]	Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(10229):1033-1034. doi: S0140-6736(20)30628-0 pmid: 32192578
[5]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X pmid: 32085846
[6]	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China[J]. Lancet, 2020, 395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7 URL
[7]	Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19[J]. Diabetes Metab Res Rev, 2020, 36(7):e3319.
[8]	Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection[EB/J]. bioRxiv, 2020. https://europepmc.org/article/PPR/PPR111788.
[9]	彭玲玲. 新型冠状病毒肺炎合并糖尿病患者的高血糖影响因素分析[J]. 中国临床药理学杂志, 2020, 36(7):1-4.
[10]	Leung C. Clinical features of deaths in the novel coronavirus epidemic in China[J]. Rev Med Virol, 2020, 30(3): e2103.
[11]	李莎, 白育庭. 糖尿病肺损伤的研究进展[J]. 湖北科技学院学报(医学版), 2014, 28(3):275-276.
[12]	Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sci China Life Sci, 2020, 63(3):457-460. doi: 10.1007/s11427-020-1637-5 pmid: 32009228
[13]	Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273. doi: 10.1038/s41586-020-2012-7
[14]	Fernandez C, Rysä J, Almgren P, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality[J]. J Intern Med, 2018, 284(4):377-387. doi: 10.1111/joim.12783 pmid: 29888466
[15]	Berbudi A, Rahmadika N, Tjahjadi AI, et al. Type 2 diabetes and its impact on the immune system[J]. Curr Diabetes Rev, 2020, 16(5):442-449. doi: 10.2174/1573399815666191024085838 pmid: 31657690
[16]	Hodgson K, Morris J, Bridson T, et al. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections[J]. Immunology, 2015, 144(2):171-185. doi: 10.1111/imm.12394 pmid: 25262977
[17]	Lam VC, Lanier LL. NK cells in host responses to viral infections[J]. Curr Opin Immunol, 2017, 44:43-51. doi: S0952-7915(16)30151-0 pmid: 27984782
[18]	Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China[J]. Lancet Respir Med, 2020, 8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5 URL
[19]	张敏, 邸丽改, 马卫国, 等. 重症新型冠状病毒肺炎与2型糖尿病的相关性研究[J]. 热带医学杂志, 2022, 22(6):827-831.
[20]	Touch S, Clément K, André S. T cell populations and functions are altered in human obesity and type 2 diabetes[J]. Curr Diab Rep, 2017, 17(9):81. doi: 10.1007/s11892-017-0900-5 URL
[21]	Wagner NM, Brandhorst G, Czepluch F, et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk[J]. Obesity (Silver Spring), 2013, 21(3):461-468. doi: 10.1002/oby.v21.3 URL
[22]	关欣, 关海霞, 谷野, 等. 新型冠状病毒肺炎患者核酸阳性持续时间延长可能与合并糖尿病相关[J]. 中华内分泌代谢杂志, 2020, 36(8):661-666.
[23]	杨芳, 朱新新, 王敏, 等. 糖尿病与非糖尿病患者感染新型冠状病毒肺炎临床结局比较[J]. 中国糖尿病杂志, 2021, 29(1):44-49.
[24]	王德平, 孙毓晗, 王信, 等. 重型及危重型新型冠状病毒肺炎合并糖尿病患者的临床特征及疾病转归[J]. 实用医学杂志, 2021, 37(24):3097-3100.
[25]	Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19[J]. Diabetes Care, 2020, 43(12):2938-2944. doi: 10.2337/dc20-1506 pmid: 32847827
[26]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X pmid: 32085846
[27]	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China[J]. Lancet, 2020, 395(10229):1054-1062. doi: S0140-6736(20)30566-3 pmid: 32171076
[28]	Wu J, Huang J, Zhu G, et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19[J]. BMJ Open Diabetes Res Care, 2020, 8(1):e001476.
[29]	Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes[J]. Cell Metab, 2020, 31(6):1068-1077. doi: S1550-4131(20)30238-2 pmid: 32369736
[30]	Toniolo A, Cassani G, Puggioni A, et al. The diabetes pandemic and associated infections: suggestions for clinical microbiology[J]. Rev Med Microbiol, 2019, 30(1):1-17. doi: 10.1097/MRM.0000000000000155 pmid: 30662163
[31]	中华医学会糖尿病学分会. 糖尿病患者合新型冠状病毒肺炎的管理建议[J]. 中华糖尿病杂志, 2020, 12(2):73-75.
[32]	中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33(1):1-10.
[33]	Torres A, Motos A, Cillóniz C, et al. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19[J]. Intensive Care Med, 2022, 48(7):850-864. doi: 10.1007/s00134-022-06726-w